In solid tumours, we identified TATs, with approved ADCs, widely expressed in non‐explored niche indications like Enfortumab vedotin (anti‐Nectin4) in lung or cervical cancer; Tisotumab vedotin (anti‐TF) in glioblastoma or pancreatic cancer; and Sacituzumab govitecan (anti‐TROP2) in pancreatic, gastric, thyroid or endometrial cancer, among others. This evidence concerns the gene TF and pancreatic neoplasm.